Key result
Immunization with whole inactivated SIV vaccine protected macaques from infection only when challenged with virus generated in human cells, confirming species-specificity of protection.
Caution against extrapolating macaque SIV results to human HIV vaccines; leaves open refined, species-matched challenge models.
Homologous SIVsm stocks were generated by passage of a macaque isolate of SIVsm (SIVsm/E660) in human CEM x 174 cells or macaque peripheral blood mononuclear cells. Macaques were immunized with whole inactivated SIV vaccine consisting of virus generated by transfection of CEM x 174 cells with the SIVsmH4 clone and were challenged with either cell-free stock. Only vaccinees challenged with virus generated in human cells were protected from infection. This confirms the species-specificity of whole inactivated vaccine-mediated protection.
No takes yet. Share an insight, caveat, or question.
Goldstein et al. (1994) studied SIV infection. Whole inactivated SIV vaccine was evaluated on Protection from infection. Immunization with whole inactivated SIV vaccine protected macaques from infection only when challenged with virus generated in human cells, confirming species-specificity of protection.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: